Navigation Links
Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
Date:4/27/2009

COPENHAGEN, April 27 /PRNewswire/ -- As a testimony to the strength of Santaris Pharma's efficient Drug Discovery Engine, the Company announced today the completion of the delivery of six cancer target drug candidates to their collaboration partner Enzon Pharmaceuticals. All six drug candidates have been designed, synthesized and selected in collaboration with Enzon, within 24 months of commencing the collaboration.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"Our collaboration with Enzon Pharmaceuticals has been very productive and goal oriented enabling both companies to benefit optimally from our ability to rationally design, discover and select potent and safe RNA targeted drugs within a short time span," said Henrik 0rum, Santaris Pharma's Chief Scientific Officer.

Santaris Pharma and Enzon Pharmaceuticals signed their agreement in 2006. As part of the agreement Santaris Pharma retains the lucrative commercial rights to the drugs within Europe. The agreement included two LNA based RNA inhibitors at the pre-clinical stage, EZN2968 against HIF-1ÿ±, and EZN3042 against Survivin, both of which are currently in Phase I studies conducted by Enzon, and the development of six additional cancer target drugs selected by Enzon which are in various stages of preclinical development.

"We are encouraged by the data generated by the first two lead candidates," said Dr. Ivan Horak, Executive Vice President of Research, Development and Chief Scientific Officer, Enzon Pharmaceuticals. "In addition, I'm pleased to see the continued validation of the Locked Nucleic Acid (LNA) technology as we continue to evaluate the additional targets in preclinical programs."

http://www.santaris.com

Santaris Pharma (founded in 2003) is a privately held biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and upfront payments.

    Contact:

    For further information, please contact
    Randi Krogsgaard, Director, Corporate Communications,
    Direct phone +45-4517-9879,
    Cell: +45-20488384,
    E-mail: rmk@santaris.com.



'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
4. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
5. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
6. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
7. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
8. Helix BioPharma to Present at the BioFinance 2009 Conference
9. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
10. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
11. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... --  MedyMatch Technology Ltd ., the data analytics healthcare company ... tools in the emergency room, announced today that it has ... Industries (IATI) BioMed Conference. The Conference is ... Life Sciences and Technology Week, and is being held May ... Tel Aviv, Israel . Gene Saragnese , ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and ... the South Texas Blood & Tissue Center, blood donations are on the decline. In fact, ... they are down 21 percent in South Texas in the last four years alone. , ...
(Date:5/23/2016)... -- Oxitec CEO Hadyn Parry will ... ET before the United States House Committee on Science, Space ... in controlling the spread of the Aedes aegypti ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has ... Trials in Brazil , Panama ...
(Date:5/23/2016)... Alto, CA (PRWEB) , ... May 23, 2016 ... ... and public interest organization focused on molecular nanotechnology, announced the winners for the ... of pioneer physicist Richard Feynman, are given in two categories, one for experiment ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):